Sustained inhibition of experimental neointimal hyperplasia with a genetically modified herpes simplex virus

Journal of Vascular Surgery

Volumn 37, Issue 6, 2003, Pages 1294-1300

  Curi, Michael A ^a,b   Skelly, Christopher L ^a,b   Meyerson, Shari L ^a,b   Baldwin, Zachary K ^a,b   Balasubramanian, Viji ^a,b   Advani, Sunil J ^a,b   Glagov, Seymour ^a,b   Roizman, Bernard ^a,b   Weichselbaum, Ralph R ^a,b   Schwartz, Lewis B ^a,b  

^a University of Chicago ^*

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTARALDEHYDE; HERPES SIMPLEX VACCINE; R849; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD FLOW; CAROTID ARTERY; CELL CULTURE; CELL SURVIVAL; COLORIMETRY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; ENDOTHELIUM CELL; GENE VECTOR; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTIMA; JUGULAR VEIN; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RABBIT; SHEAR STRESS; SMOOTH MUSCLE FIBER; UMBILICAL ARTERY; UMBILICAL VEIN; VIRUS RECOMBINANT; ANIMAL; DISEASE MODEL; DRUG EFFECT; GENETICS; HYPERPLASIA; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANIMALS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENETIC VECTORS; HUMANS; HYPERPLASIA; MALE; MYOCYTES, SMOOTH MUSCLE; RABBITS; SIMPLEXVIRUS; TUNICA INTIMA; UMBILICAL ARTERIES; VASCULAR DISEASES;

EID: 0038748228     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-5214(02)75333-0     Document Type: Article

References (33)

1. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-93.
2. Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, Lespèrance J. Long-term fate of bypass grafts: The Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences. Circulation 1985;72(suppl V):V-71-8.
3. Donaldson MC, Mannick JA, Whittemore AD. Causes of primary graft failure after in situ saphenous vein bypass grafting. J Vasc Surg 1992;15:113-20.
4. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: A review. J Vasc Surg 1991;13:885-91.
5. 134.5, a gene nonessential for growth in culture. Science 1990;250:1261-6.
6. Skelly CL, Curi MA, Meyerson SL, Hari D, Vosicky J, Advani SJ, et al. Prevention of restenosis by a herpes simplex virus mutant capable of controlled long-term expression in vascular tissue in vivo. Gene Ther 2001;8:1840-6.
7. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Can Res 1997;57:1502-9.
8. Culver KW. Methods for gene transfer and repair. In: Culver KW, editor. Gene therapy: A primer for physicians. Larchmont, NY: Mary Ann Liebert, 1996. p 3-45.
9. Lachmann RH, Efstathiou S. The use of herpes simplex virus-based vectors for gene delivery to the nervous system. Molec Med Today 1997;3:404-11.
10. Wolfe D, Goins WF, Kaplan TJ, Capuano SV, Fradette J, Murphey-Corb M, et al. Herpes virus-mediated systemic delivery of nerve growth factor. Molec Ther 2001;3:61-9.
11. Advani SJ, Sibley GS, Song PY, Hallahan DE, Kataoka Y, Roizman B, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther 1998;5:160-5.
12. Chambers R, Gillespic GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, et al. Comparison of genetically engineered herpes simplex virus for the treatment of brain tumors in SCID mouse model of human glioma. Proc Natl Acad Sci USA 1995;92:1411-5.
13. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W, et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Molec Ther 2000;2:114-20.
14. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase 1 trial. Gene Ther 2000;7:867-874.
15. Miyatake S-I, Yukawa H, Toda H, Matsuoka N, Takahashi R, Hashimoto N. Inhibition of rat vascular smooth muscle cell proliferation in vitro and in vivo by recombinant replication-competent herpes simplex virus. Stroke 1999;30:2431-8.
16. Huard J, Goins WF, Fink DJ. Herpes simplex virus type I vector mediated gene transfer to muscle. Gene Ther 1995;2:385-92.
17. Feero WG, Rosenblatt JD, Huard J, Watkins SC, Epperly M, Clemens PR, et al. Viral gene delivery to skeletal muscle: Insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Human Gene Ther 1997;8:371-80.
18. Huard J, Feero G, Watkins SC, Hoffman EP, Rosenblatt DJ, Glorioso JC. The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. J Virol 1996;70:8117-23.
19. Coffin RS, Howard MK, Cumming DVE, Dollery CM, McEwan J, Yellon DM, et al. Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors. Gene Ther 1996;3:560-6.
20. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-6.
21. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994;54:3963-6.
22. Diloo D, Rill D, Entwistle C, Boursnell M, Zhong W, Holden W, et al. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood 1997;89:119-27.
23. 134.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci USA 1994;91:5247-51.
24. Nakano K, Todo T, Chijiiwa K, Tanaka M. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther 2001;3:431-7.
25. Oyama M, Ohigashi T, Hoshi M, Murai M, Uyemura K, Yazaki T. Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207. J Urol 2001;165:1274-8.
26. Luna MC, Chen X, Wong S, Tsui J, Rucker N, Lee AS, et al. Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter. Cancer Res 2002;62:1458-61.
27. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:815-6.
28. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995;95:2260-8.
29. Moawad J, Leiden JM, Meyerson SI, Skelly CL, Chang MW, Schwartz LB. Adenoviral-mediated gene transfer in experimental vein grafts using clinically-relevant exposure times, pressures, and viral concentrations. Ann Vasc Surg 2001;15:367-73.
30. Schwartz LB, Moawad J, Svensson EC, Tufts RL, Meyerson SL, Baunoch D, et al. Adenoviral-mediated transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J Vasc Surg 1999;29:874-83.
31. Eslami MH, Gangadharan SP, Sui XX, Rhynhart KK, Snyder RO, Conte MS. Gene delivery to in situ veins: Differential effects of adenovirus and adeno-associated viral vectors. J Vasc Surg 2000;31:1149-59.
32. Feldman LJ, Tahlil O, Steg PG. Adenovirus-mediated arterial gene therapy for restenosis: Problems and perspectives. Semin Inter Cardiol 1996;1:203-8.
33. Kibbe MR, Tzeng E, Gleixner SL, Watkins SC, Kovesdi I, Lizonova A, et al. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 2001;34:156-65.